Cargando…

A prognostic signature based on three-genes expression in triple-negative breast tumours with residual disease

Residual disease after neoadjuvant chemotherapy (NAC) in triple-negative breast cancer (TNBC) is related with poor prognosis; however, the risk of recurrence after 3 years from surgery, becomes similar to other breast cancer subtypes indicating that TNBC is composed of tumours of different prognosis...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pinto, Joseph A, Araujo, Jhajaira, Cardenas, Nadezhda K, Morante, Zaida, Doimi, Franco, Vidaurre, Tatiana, Balko, Justin M, Gomez, Henry L
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2016
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5685288/ https://www.ncbi.nlm.nih.gov/pubmed/29263808 http://dx.doi.org/10.1038/npjgenmed.2015.15

Ejemplares similares

Effect of CCL5 expression in the recruitment of immune cells in triple negative breast cancer
por: Araujo, Jhajaira M., et al.
Publicado: (2018)

Prognostic Capability of TNBC 3-Gene Score among Triple-Negative Breast Cancer Subtypes
por: Araujo, Jhajaira M., et al.
Publicado: (2022)

PIK3CA mutation in non-metastatic triple-negative breast cancer as a potential biomarker of early relapse: A case report
por: Valencia, Guillermo Arturo, et al.
Publicado: (2021)

Repeated observation of immune gene sets enrichment in women with non-small cell lung cancer
por: Araujo, Jhajaira M., et al.
Publicado: (2016)

Immunotherapy in triple-negative breast cancer: A literature review and new advances
por: Valencia, Guillermo Arturo, et al.
Publicado: (2022)

Neutrophil-to-lymphocyte ratio predicts early mortality in females with metastatic triple-negative breast cancer
por: de la Cruz-Ku, Gabriel, et al.
Publicado: (2020)

Subpopulation treatment effect pattern plot analysis: a prognostic model for distant recurrence-free survival to estimate delayed adjuvant chemotherapy initiation effect in triple-negative breast cancer
por: Morante, Zaida, et al.
Publicado: (2023)

In silico evaluation of DNA Damage Inducible Transcript 4 gene (DDIT4) as prognostic biomarker in several malignancies
por: Pinto, Joseph A., et al.
Publicado: (2017)

Triple-negative breast cancer in Peru: 2000 patients and 15 years of experience
por: De-la-Cruz-Ku, Gabriel, et al.
Publicado: (2020)

Patterns of Mutation Enrichment in Metastatic Triple-Negative Breast Cancer
por: Saravia, César H, et al.
Publicado: (2019)

Landscape of germline BRCA1/BRCA2 variants in breast and ovarian cancer in Peru
por: Ferreyra, Yomali, et al.
Publicado: (2023)

Gender and outcomes in non-small cell lung cancer: an old prognostic variable comes back for targeted therapy and immunotherapy?
por: Pinto, Joseph A, et al.
Publicado: (2018)

Tumor infiltrating lymphocytes in triple negative breast cancer receiving neoadjuvant chemotherapy
por: Castaneda, Carlos A, et al.
Publicado: (2016)

An immunological signature to predict outcome in patients with triple-negative breast cancer with residual disease after neoadjuvant chemotherapy
por: Blaye, C., et al.
Publicado: (2022)

A nationwide pilot study on breast cancer screening in Peru
por: Araujo, Jhajaira M, et al.
Publicado: (2023)

Comparison of clinical and magnetic resonance imaging findings of triple-negative breast cancer with non-triple-negative tumours
por: Yetkin, Duygu İmre, et al.
Publicado: (2021)

Are triple-negative tumours and basal-like breast cancer synonymous?
por: Rakha, Emad A, et al.
Publicado: (2007)

ctDNA and residual cancer burden are prognostic in triple-negative breast cancer patients with residual disease
por: Stecklein, Shane R., et al.
Publicado: (2023)

Distinct microbiological signatures associated with triple negative breast cancer
por: Banerjee, Sagarika, et al.
Publicado: (2015)

Identification of immunosuppressive signature subtypes and prognostic risk signatures in triple-negative breast cancer
por: Ding, Ran, et al.
Publicado: (2023)

Advances in Tumour-Infiltrating Lymphocytes for Triple-Negative Breast Cancer Management
por: Gorenšek, Rok, et al.
Publicado: (2023)

PIK3CA mutations in androgen receptor-positive triple negative breast cancer confer sensitivity to the combination of PI3K and androgen receptor inhibitors
por: Lehmann, Brian D, et al.
Publicado: (2014)

Cytotoxic Lymphocyte-Related Gene Signature in Triple-Negative Breast Cancer
por: Han, Yiqun, et al.
Publicado: (2023)

Multi-omics analysis identifies therapeutic vulnerabilities in triple-negative breast cancer subtypes
por: Lehmann, Brian D., et al.
Publicado: (2021)

EPHB6 augments both development and drug sensitivity of triple-negative breast cancer tumours
por: Toosi, Behzad M., et al.
Publicado: (2018)

Are triple-negative tumours and basal-like breast cancer synonymous? Authors' response
por: Kreike, Bas, et al.
Publicado: (2007)

Optimized tumour infiltrating lymphocyte assessment for triple negative breast cancer prognostics
por: Balkenhol, Maschenka CA., et al.
Publicado: (2021)

Prognostic Factors for Triple-Negative Breast Cancer with Residual Disease after Neoadjuvant Chemotherapy
por: Li, Zhijun, et al.
Publicado: (2023)

Targeting EphA2 impairs cell cycle progression and growth of basal-like/triple-negative breast cancers
por: Song, W, et al.
Publicado: (2017)

A three-long noncoding RNA signature as a diagnostic biomarker for differentiating between triple-negative and non-triple-negative breast cancers
por: Liu, Man, et al.
Publicado: (2017)

Antagonists of growth hormone-releasing hormone suppress in vivo tumor growth and gene expression in triple negative breast cancers
por: Perez, Roberto, et al.
Publicado: (2012)

Identification of long non-coding RNA signatures in triple-negative breast cancer
por: Tian, Tian, et al.
Publicado: (2018)

Autophagy-related prognostic signature for survival prediction of triple negative breast cancer
por: Yang, Qiong, et al.
Publicado: (2022)

An EMT-Related Gene Signature to Predict the Prognosis of Triple-Negative Breast Cancer
por: Zhang, Bo, et al.
Publicado: (2023)

Stemness signature and targeted therapeutic drugs identification for Triple Negative Breast Cancer
por: Gul, Samina, et al.
Publicado: (2023)

Primary cutaneous T-cell lymphoma: experience from the Peruvian National Cancer Institute
por: Ruiz, Rosana, et al.
Publicado: (2017)

The prognostic value of tumour–stroma ratio in primary breast cancer with special attention to triple-negative tumours: a review
por: Kramer, C. J. H., et al.
Publicado: (2018)

AR negative triple negative or “quadruple negative” breast cancers in African American women have an enriched basal and immune signature
por: Davis, Melissa, et al.
Publicado: (2018)

Age-related mutational signature negatively associated with immune activity and survival outcome in triple-negative breast cancer
por: Chen, Hao, et al.
Publicado: (2020)

Metronomic chemotherapy for non-metastatic triple negative breast cancer: Selection is the key
por: Rabanal, Connie, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_4g4inh2qtoffkh77g67eakhv0q